CGEM
Cullinan Therapeutics, Inc.·Healthcare
15.52
0.388%(+0.06)
Close PriceLast Updated: — ET
52W L: $5.6852W H: $16.74
CGEM NEWS
globenewswire.com
1d ago
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of RA study to be presented Initial data from the first multi-dose cohort of velinotamig study also to be shared Leading key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser to share clinical perspectives The Company will host the in-person event for analysts and institutional investors on Wednesday, June 10, starting at 8:30 a.m. ET in New York City CAMBRIDGE, Mass.
globenewswire.com
May 19
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML
globenewswire.com
May 18
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that initial clinical data from two ongoing Phase 1 studies evaluating CLN-978, a subcutaneously administered CD19xCD3 T cell engager, will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology being held June 3-6, 2026 in London, United Kingdom.
gurufocus.com
May 18
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
globenewswire.com
May 7
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA; PDUFA target action date of February 27, 2027 Cash and investments of $393.3 million as of March 31, 2026; runway into 2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the first quarter ended March 31, 2026.
seekingalpha.com
Apr 30
Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst
Cullinan Therapeutics's Zipalertinib NDA has been accepted, making its February 27, 2027, PDUFA date their clearest near-term catalyst. Zipalertinib targets EGFR exon 20 insertion NSCLC, a niche but still meaningful demographic that could expand over time with more trials for new indications. CGEM's CLN-978, Velinotamig, and CLN-049 add other interesting assets in their pipeline across autoimmune disease and AML.
